| Nulojix (belatacept) / BMS |
NCT04046549: A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant |
|
|
| Completed | 2a | 25 | US | Belatacept, VIB4920, Thymoglobulin, Methylprednisolone | Viela Bio (acquired by Horizon Therapeutics) | Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation | 07/22 | 03/23 | | |
ACTRN12619000268145: A multi-centre trial of a new immunosuppression regime for pancreatic islet transplant recipients |
|
|
| Recruiting | 2 | 15 | | | The University of Sydney, JDRF Australia | Hypoglycaemia Unawareness, Type 1 Diabetes, Islet graft survival | | | | |
2019-001510-42: Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure. Intérêt du belatacept comme traitement immunosuppresseur non néphrotoxique, chez des transplantés cardiaques à risque d’insuffisance rénale chronique. |
|
|
| Not yet recruiting | 2 | 25 | Europe | BELATACEPT, Powder for solution for injection, Nulojix 250mg, poudre pour solution à diluer pour perfusion | CHU de Nantes, CHU de Nantes | Early graft dysfunction after heart transplant Dysfonction précoce du greffon après greffe cardiaque, Early graft dysfunction after heart transplant Dysfonction précoce du greffon après greffe cardiaque, Diseases [C] - Symptoms and general pathology [C23] | | | | |
BELACOEUR, NCT04180085: Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure |
|
|
| Recruiting | 2 | 25 | Europe | Belatacept Injection | Nantes University Hospital | Heart Transplant Failure | 12/24 | 12/24 | | |
| Not yet recruiting | 2 | 66 | US | Belatacept, NULOJIX, Tacrolimus, Prograf, Mycophenolate Mofetil/Sodium, CellCept, Myfortic, Prednisone | National Institute of Allergy and Infectious Diseases (NIAID) | Heart Transplant | 01/28 | 01/28 | | |
| Active, not recruiting | 2 | 87 | US | Belatacept, Nulojix, Abatacept, Orencia | Emory University | Renal Transplant Recipient | 06/26 | 06/26 | | |
| Recruiting | 2 | 12 | US | Belatacept, Nulojix, Tacrolimus, Tacrolimus taper, Mycophenolate Mofetil, MMF, Corticosteroid, CS | NYU Langone Health, Bristol-Myers Squibb | Heart Transplantation | 02/25 | 02/25 | | |
| Recruiting | 2 | 90 | US | TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids | ITB-Med LLC | Renal Transplantation | 07/25 | 10/26 | | |
NCT02310867: Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy |
|
|
| Recruiting | 2 | 50 | US | Belatacept, Nulojix, Hand transplant | Linda Cendales | Immunosuppression | 12/27 | 06/28 | | |
| Recruiting | 2 | 200 | Canada, US | Sirolimus, AY 22-989, Rapamune, Rapamycin, Belatacept, Nulojix, Mycophenolate Mofetil, CellCept, MMF, Tacrolimus (Group1), FK-506, FR-900506, Prograf, Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2) | National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Transplant | 11/28 | 11/28 | | |
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists |
|
|
| Completed | 1/2 | 10 | US | lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic® | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation | Living-Donor Kidney Transplant, Kidney Transplant Recipients | 09/23 | 09/23 | | |
| Recruiting | 1/2 | 15 | US | carfilzomib, Kyprolis®, belatacept, Nulojix®, Bone marrow aspiration | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc. | Highly Sensitized Prospective Kidney Transplant Recipients | 02/27 | 02/28 | | |
| Recruiting | 1/2 | 5 | US | Belatacept Injection, proteasome inhibitor | University of Chicago | Kidney Transplantation, End Stage Kidney Disease (ESRD) | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 15 | US | daratumumab, Darzalex®, immunoglobulin G1 kappa human monoclonal antibody, IgG1k human mAb, belatacept, Nulojix®, Bone marrow aspiration | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc. | Highly Sensitized Prospective Kidney Transplant Recipients | 03/27 | 04/28 | | |
